Dynamic hormone profiling for diagnosing primary aldosteronism
Dynamic Hormone Profiling and Multimodal Data Capture in Primary Aldosteronism
Haukeland University Hospital · NCT06495983
This study is testing a new way to measure hormone levels in people who might have primary aldosteronism to see if it can help diagnose the condition more easily and accurately.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 80 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Haukeland University Hospital (other) |
| Locations | 1 site (Bergen) |
| Trial ID | NCT06495983 on ClinicalTrials.gov |
What this trial studies
This observational study utilizes a 24-hour microdialysis methodology to perform dynamic multisteroid adrenal hormone profiling in patients with suspected or confirmed primary aldosteronism (PA). It aims to capture the rhythmic nature of aldosterone and related hormones while simultaneously monitoring blood pressure, glucose levels, sleep patterns, activity levels, and food intake. The goal is to develop a novel, sensitive, and user-friendly diagnostic procedure that improves upon the current cumbersome diagnostic methods for PA. By comparing hormone profiling results with various physiological parameters, the study seeks to enhance the understanding and diagnosis of PA.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 to 70 years who are suspected of having primary aldosteronism or have a confirmed diagnosis according to Endocrine Society criteria.
Not a fit: Patients under 18 or over 70 years, pregnant individuals, or those with known adrenal failure or on interfering medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to a more accurate and efficient diagnostic procedure for primary aldosteronism, potentially reducing the risk of complications associated with undiagnosed cases.
How similar studies have performed: While the approach of dynamic hormone profiling is innovative, similar studies have shown promise in improving diagnostic accuracy for hormonal disorders.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria Age 18 to 70 years Suspected PA admitted for diagnostic saline infusion testing or confirmed PA diagnosis according to Endocrine Society criteria.. Written informed consent Exclusion criteria * Age \<18 or \> 70 years. * Pregnancy. * Known adrenal failure and/or on steroid therapy (oral, inhaled, parenteral or topical) or other interfering medication.
Where this trial is running
Bergen
- Haukeland University Hospital — Bergen, Norway (RECRUITING)
Study contacts
- Principal investigator: Marianne Aarda Grytaas, MD PhD — Haukeland University Hospital
- Study coordinator: Marianne Aardal Grytaas, MD PhD
- Email: marianne.grytaas@helse-bergen.no
- Phone: 004741545435
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Mineralocorticoid Excess, Primary Aldosteronism, Hypercortisolism, aldosterone